Aclaris Therapeutics enters amended at-the-market equity sales agreement with Leerink, Cantor

• Aclaris Therapeutics entered a second amended and restated at-the-market equity distribution agreement with Leerink Partners and Cantor Fitzgerald.
• Allows sales of common stock from time to time at the company’s discretion under a Form S-3 registration statement.
• Replaces the February 27, 2025 sales agreement that provided for up to USD 100 million of common stock sales.
• Sales agents to use commercially reasonable efforts based on company instructions; 3% commission on gross proceeds.
• No obligation to sell shares; program ends upon termination under the agreement’s terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-092128), on August 06, 2026, and is solely responsible for the information contained therein.